Abstract
Introduction
Patients with diabetes mellitus (DM) are at increased risk of ischaemic events post-acute coronary syndrome (ACS). 1, 2 Although the augmented atherothrombotic risk in this population is multifactorial, 3 the increased aggregation of platelets in DM is a main risk factor 4 requiring more effective platelet-inhibiting therapeutic strategies such as those based on ticagrelor and prasugrel. To complete the picture, DM patients often present on the one hand with a more severe and diffuse coronary disease, 5, 6 while on the other they are at increased risk of bleeding, mainly as consequence of reduced renal function. The ultimate result is a short dual antiplatelet therapy (DAPT) time duration distribution for those patients. 7, 8 It has been observed that both ticagrelor and prasugrel improve outcomes when compared with clopidogrel. 9, 10 These results have been shown to be even more solid among diabetes patients, particularly those using prasugrel. 10 However, ticagrelor has been proved to exert a similar or more marked inhibition of adenosine diphosphate-induced platelet reactivity in comparison with prasugrel, in patients with ACS. 11 Here, the outcomes of patients with ACS and DM receiving prasugrel or ticagrelor are compared using data from the large multicentre, international REgistry of New Antiplatelets in patients with Myocardial Infarction (RENAMI).
Methods

Study population
The study population was selected from RENAMI (https:// renami.000webhostapp.com/), which extends from 2012 to 2016, including 12 European centres. All patients gave oral and/or written informed consent to be enrolled in the registry and consented to be contacted for telephone and/or onsite follow-up visits.
All patients underwent coronary angiography for ACS (ST-segment elevation myocardial infarction (STEMI), non-STEMI or unstable angina) and were treated with DAPT based on ticagrelor or prasugrel.
Cohort of interest
Among the whole RENAMI cohort, patients with diabetes were selected and analysed. Diabetic status and whether or not they were on insulin treatment were assessed at the time of enrollment. Patients were divided into two groups according to the applied DAPT strategy at discharge (aspirin and prasugrel vs. aspirin and ticagrelor). Prasugrel and ticagrelor doses were chosen according to current guidelines: 5 or 10 mg/day and 90 mg twice a day, respectively.
Clinical variables
Diabetic status was assessed at discharge so as to include during hospitalisation de novo diagnosis. All clinical characteristics (burden of cardiovascular risk factors and clinical presentation), as well as interventional (access site, kind of coronary disease and treatment) and outcome data, were collected with the supervision of a trained study coordinator in each centre participating in RENAMI. The institutional review board of each centre approved participation in RENAMI. For patients with multivessel disease, completeness of revascularisation during index percutaneous coronary intervention (PCI) or staged was left at the physicians' discretion.
Endpoint and follow-up
Net adverse cardiovascular events (NACEs; a composite and mutually exclusive endpoint of all-cause death, stroke, myocardial infarction and BARC 3-5 bleeding) was the primary endpoint, while major adverse cardiovascular events (MACEs; a composite and mutually exclusive endpoint of death, stroke and MI) was the secondary one. Single components of NACEs and MACEs were considered as co-secondary endpoints, along with stent thrombosis and BARC 2-5 bleeding. Follow-up was censored for each patient at the end of the DAPT. All events were adjudicated in each centre by dedicated physicians through clinical examination.
Statistical analysis
Continuous variables are presented as mean ± standard deviation or median with the interquartile range, categorical variable are presented in terms of frequency (%). Categorical variables were compared with the Fisher's exact test. Parametric distribution of continuous variables was tested graphically and with the Kolmorogov-Smirnov test, and the appropriate analyses were used in accordance with the results. Propensity score with matching analysis was performed as follows: first, logistic regression analysis was carried out on all baseline features that differed between prasugrel and ticagrelor, and matching was computed after division into quintiles and the application of the method of nearest neighbour on the estimated propensity score. 12 Calibration was assessed by applying the HosmerLemeshow test, and accuracy was assessed using the area under the curve approach. Standardised differences were evaluated before and after matching to evaluate the performance of the model. The cumulative incidences of NACEs and MACEs were calculated using the Kaplan-Meier method using DAPT time duration as the median follow-up analysis and differences among groups were analysed using a stratified log-rank test. Statistical analysis was performed using the statistical software package SPSS version 21.0. Differences were considered statistically significant at α=0.05.
Results
Of the 4424 patients enrolled in RENAMI, 1324 (30%) presented with diabetes at the time of enrollment. Of those, 462 (34.9%) patients were discharged on aspirin and prasugrel and 862 (63.1%) were discharged on aspirin and ticagrelor (see Supplementary Appendix Figure 1 ).
Baseline and procedural characteristics are summarised in Supplementary 
001).
After 18±6 months, the rate of the primary composite outcome did not differ between prasugrel and ticagrelortreated patients. NACEs and MACEs occurred in 6.5% versus 6.4% (P=0.94) and 5.4% versus 4.8% (P=0.60) of the prasugrel and ticagrelor populations, respectively (see Supplementary Table 2 ). Single components of NACEs and MACEs occurred with similar frequency in the prasugrel and ticagrelor groups.
Matched study cohort after propensity score analysis
After propensity score with matching analysis, 386 patients treated with prasugrel and 386 treated with ticagrelor with similar clinical presentation, baseline risk factors and interventional features were selected (Table 1) .
After 19±5 months, NACEs rates were similar in the prasugrel group and the ticagrelor group (6.7% vs. 4.1%, P=0.11), with similar MACEs incidence (5.4% vs. 3.4%, P=0.16, see Table 2 ). Ticagrelor reduced the risk of death (2.8% vs. 0.8%, P=0.031) and BARC 2-5 bleeding (6.0% vs. 2.6%, P=0.02) with a clear, but not significant, trend for less BARC 3-5 bleeding (2.3% vs. 0.8%, P=0.08). No relevant differences in AMI, stroke and STEMI were observed between the two groups. Kaplan-Meier analysis highlighted a similar incidence of NACEs, MACEs and BARC 3-5 bleeding in both groups (log rank P=0.26, 0.54 and 0.37, respectively) and a statistically significant higher mortality in the prasugrel group (log rank P=0.029) ( Figures  1 and 2 and Supplementary Appendix Figures 2 and 3) .
Discussion
To the best of our knowledge this is the largest prospective and propensity matched investigation on patients with ACS and DM comparing prasugrel with ticagrelor.
The main findings we observed are:
• diabetes patients with ACS receiving prasugrel or ticagrelor differed in general and procedural features at baseline; • NACEs and MACEs were similar in patients treated with prasugrel or ticagrelor; • patients treated with ticagrelor reported a lower incidence of mortality and of bleeding.
Type 2 DM is strongly related to an increased risk of adverse cardiovascular events and mortality in patients treated for ACS. 1,2 Coronary lesion complexity is often challenging for both interventional cardiology and cardiac surgeons. 13, 14 The pathophysiology of these reports can be found in several cardiometabolic risk factors linked to DM, such as hyperglycemia, hyperlipidemia, chronic kidney disease and particularly the inflammatory and pro-thrombotic environment typical of this type of patient. 4, 15 It is therefore mandatory to optimise antithrombotic strategy considering the well-known higher platelet reactivity of DM patients 16, 17 and the prognostic implication even when treated with antiplatelet agents. 18 Newer P2Y12 inhibitors have shown more benefit in terms of strong cardiovascular outcomes than clopidogrel, 19, 20 even in the setting of DM 9, 10 with an apparent superiority of prasugrel in this subset. 10 The baseline characteristics of ACS patients treated with prasugrel or ticagrelor were different in our real life observational study. The prasugrel cohort was younger, with a lower burden of previous cardiovascular events (stroke and AMI), better renal function and left ventricular ejection fraction compared to the ticagrelor group. These differences are a consequence of guideline recommendations, 21, 22 originated by safety considerations from the TRITON TIMI trial 20 in which emerged an unfavourable net clinical benefit in patients with previous stroke, older than 75 years and with a lower body max index. For these reasons, patients who receive prasugrel often have a lower ischaemic and haemorrhagic risk profile. In the absence of direct randomised comparison, our analysis with propensity matching tends to reduce the impact of this baseline heterogeneity, so that less ambiguous, more solid conclusions can be drawn in terms of the efficacy-safety profile of these two antiplatelet agents, particularly for a high-risk population as the one under study here. No significant differences emerged in terms of NACEs and MACEs in our study after propensity adjustment. Up to now, only the PRAGUE-18 trial 23 has tested in a direct and randomised comparison prasugrel and ticagrelor in ACS patients, showing neutral results at one year of follow-up both in terms of ischaemic as well as bleeding incidence. However, apart from some methodological limitations, the sample size was largely underpowered for hard outcome conclusions and economically driven downgrading to clopidogrel therapy was consistent (more than 40%) because of the absence of drug reimbursement to enrolled patients. Furthermore, Motovska and colleagues 23 did not focus on a real high-risk population as we did, even if a sub-analysis on the small diabetes group did not show significant interaction on the main conclusions of the trial. Apart from this randomised controlled trial (RCT), an adjusted indirect meta-analysis of pivotal RCTs 24 showed a substantial equivalence between prasugrel and ticagrelor in ACS. More recently, Watti et al. 25 published another systematic revision on this issue, matching both randomised and observational studies comparing the new P2Y12 inhibitors and concluding on a slight better profile for prasugrel, mainly driven by observational and not always adjusted data. Nevertheless, all previously cited papers lack a specific conclusion on diabetes patients. Two sub-analyses from the main trials have been published on this subset. 9, 10 In the substudy of TRITON TIMI, 10 prasugrel benefit seemed to increase in diabetes patients compared to those without diabetes, with a clear net clinical benefit also considering bleeding events. On the other hand, James et al. reported a substantial reproducibility of the results of ticagrelor also in the DM cohort, without reaching statistical significance, probably because of the lack of required power. 9 Different studies demonstrated a poorer outcome of clopidogrel in diabetes patients, depending on pharmacokinetic and pharmacodynamic considerations, particularly on the above-mentioned higher platelet reactivity in DM. 17, 18 Prasugrel and ticagrelor have shown their superiority over clopidogrel in terms of faster and stronger platelet inhibition. 26, 27 If a real difference exists between these two drugs, the ability to inhibit platelet aggregation must be the central element. In a pharmacodynamics study, Franchi et al. 11 observed that ticagrelor has a similar or even greater ability of platelet aggregation inhibition versus prasugrel, supporting our result in a clinical setting.
Patients treated with ticagrelor were associated with a lower mortality incidence, mainly driven by lower bleeding rates, compared to prasugrel-treated patients. In addition to its main action of blocking P2Y12 receptors, ticagrelor has been shown to reduce adenosine intracellular uptake, with a consequent increase in its circulating levels. 28 This collateral action could explain the not so rare induction of dyspnoea, as well as some pleiotropic activities such as vasodilation and furthermore inflammatory modulation, with the potential for cardiovascular prognosis improvement. 29 An elegant study by Jeong et al. 30 compared, in a randomised manner, prasugrel with ticagrelor in diabetes patients with NSTEMI ACS and treated with PCI and stenting. A significant reduction of inflammatory markers was evident in the ticagrelor group, stressing the idea of a possible clinical benefit in this population. Despite this, due to reduced sample size, dedicated and powered RCTs on this high-risk population are needed. Moreover, in the present registry an overall low risk of adverse events was noted, especially when compared with the data presented by Sahlen et al. 31 All patients in our registry were treated with PCI, which was shown to reduce mortality in ACS patients, potentially explaining the present results. Our conclusions partly contrast with previous findings that seem to suggest a better performance for prasugrel among diabetes patients. 32 Larger sample sizes and direct randomised comparisons are desirable definitively to throw light on this shadow.
Limitations
The main limitation of our study is the small sample size so that our conclusions on a secondary outcome with a low incidence such as death must be considered as hypothesis generating only. The reduced sample size may on one hand generate a type II statistical error explaining the lack of difference in primary and secondary endpoints, and on the other may lead to a type I error being related to the difference in death rates. Moreover, as with all observational studies our general analysis suffers from selection and adjudication biases even if it directly reflects real-life practice. Our propensity score matching, furthermore, even if not comparable to a RCT, showed good accuracy (area under the curve of 0.78) and discrimination (P=0.8, Hosmer-Lemeshow test). Lack of detailed data on each single BARC class and on the incidence of fatal bleeding did not allow a more comprehensive analysis of bleeding burden between the two investigated cohorts. Nevertheless, the composite BARC 2-5 and BARC 3-5 classes allow a reliable interpretation. No data on the incidence of switching between different P2Y12 inhibitors during the acute phase in index hospitalisation were available, even if analysis was conducted on discharge prescribed therapy.
Conclusions
Diabetes patients with ACS seem to benefit equally in terms of MACEs and NACEs from ticagrelor or prasugrel use. Ticagrelor was associated with a significant reduction in all-cause death and bleeding, without differences in recurrent ischaemic events which should be confirmed in dedicated RCTs.
